オフロキサシン(OFLX)を中心とした各種ニューキノロン剤投与後の血清ならびに前立腺組織内濃度

Abstract

良性前立腺肥大症患者25例に於いて, 6例にNFLX(ノルフロキサシン), 10例にCPFX(シプロフロキサシン), 5例にTFLX(トスフロキサシン), 4例にENX(エノキサシン), 全例に同時にOFLXを投与した。用量は, TFLXの150mg以外は100mgであった。OFLXの血清中濃度はNFLX, CPFX, TFLX, 或いはENXのそれに比し有意に高かった。OFLXの前立腺組織中濃度はCPFX或いはTFLXのそれに比し有意に高かった。組織/血清中濃度比は各薬物間で有意差がなかった。OFLXの高い組織中濃度は高い血清中濃度によると思われた

Twenty five patients with benign prostate hypertrophy were administered ofloxacin (OFLX) simultaneously with norfloxacin (NFLX) in 6 patients, ciprofloxacin (CPFX) in 10, tosfloxacin (TFLX) in 5 and enoxacin (ENX) in 4 patients. The dose of these new quinolones was 100 mg (except 150 mg of TFLX). Their concentrations in the serum and the prostate tissue were measured by high performance liquid chromatography (HPLC). The serum concentration of OFLX was significantly higher than that of NFLX, CPFX, TFLX or ENX. The prostate tissue concentration of OFLX was significantly higher than that of CPFX or TFLX. The ratio of tissue versus serum concentration of each new quinolone agent was not significantly different. The high OFLX tissue concentration appeared to be caused by the high serum concentration.